Dan Passeri, CEO, Cue Biopharma discusses their proprietary Immuno-STAT(TM) platform. Cue Biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases.
